EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial

Roser Ayats-Vidal, Montserrat Bosque-García, Begoña Cordobilla iD, Oscar Asensio-De la Cruz, Miguel García-González, Jesús Castro-Marrero iD, Irene López-Rico, Joan Carles Domingo iD

Journal of Clinical Medicine · 26.05.2023 · 12 (11) · 3704

DOI: 10.3390/jcm12113704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.05.2023. Verfasst von Roser Ayats-Vidal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Parc Ta…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bernola-Vallribera Foundation, Sant Josep 2018, Taulí Research and Innovation 2018.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We characterized the fatty acid profiles in the erythrocyte membrane of pediatric patients with cystic fibrosis (CF) receiving highly concentrated docosahexaenoic acid (DHA) supplementation (Tridocosahexanoin-AOX® 70%) at 50 mg/kg/day (n = 11) or matching placebo (n = 11) for 12 months. The mean age was 11.7 years. The DHA group showed a statistically significant improvement in n-3 polyunsaturated fatty acids (PUFAs), which was observed as early as 6 months and further increased at 12 months. Among the n-3 PUFAs, there was a significant increase in DHA and eicosapentaenoic acid (EPA). Additionally, a statistically significant decrease in n-6 PUFAs was found, primarily due to a decrease in arachidonic acid (AA) levels and elongase 5 activity. However, we did not observe any changes in linoleic acid levels. The long-term administration of DHA over one year was safe and well tolerated. In summary, the administration of a high-rich DHA supplement at a dose of 50 mg/kg/day for one year can correct erythrocyte AA/DHA imbalance and reduce fatty acid inflammatory markers. However, it is important to note that essential fatty acid alterations cannot be fully normalized with this treatment. These data provide timely information of essential fatty acid profile for future comparative research.

Schlagwörter

Stichwörter der Autor:innen

cystic fibrosisdocosahexaenoic acideicosapentaenoic acidfatty acidsomega-3pancreatic insufficiencyrandomized controlled study

Autor:innen und Institutionen

  • Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Parc Taulí Hospital Universitari, Universitat Autònoma de Barcelona, Parc Tau…
  • Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, E-08028 Barcelona, Spain.
  • ME/CFS Research Unit, Division of Rheumatology, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, E-08035 Barcelona, Spain.
  • Pharmacy Department, Institut d'Investigació I Innovació Parc Taulí (I3PT-CERCA), Parc Taulí Hospital Universitari, Universitat Autònoma de Barcelona, E-08208 Sabadell, Spain.

ORCID-Profile: Begoña Cordobilla, Jesús Castro-Marrero, Joan Carles Domingo

Förderung

  • Bernola-Vallribera Foundation, Sant Josep 2018
  • Taulí Research and Innovation 2018

Zitieren

APA

Ayats-Vidal, R., Bosque-García, M., Cordobilla, B., Asensio-De la Cruz, O., García-González, M., Castro-Marrero, J., López-Rico, I., & Domingo, J. C. (2023). Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial. Journal of Clinical Medicine, 12(11), 3704. https://doi.org/10.3390/jcm12113704

Vancouver

Ayats-Vidal R, Bosque-García M, Cordobilla B, Asensio-De la Cruz O, García-González M, Castro-Marrero J, et al. Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial. Journal of Clinical Medicine. 2023;12(11):3704. doi:10.3390/jcm12113704

BibTeX
@article{AyatsVidal2023,
  author = {Ayats-Vidal, Roser and Bosque-García, Montserrat and Cordobilla, Begoña and Asensio-De la Cruz, Oscar and García-González, Miguel and Castro-Marrero, Jesús and López-Rico, Irene and Domingo, Joan Carles},
  title = {Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {11},
  pages = {3704},
  doi = {10.3390/jcm12113704}
}
Kostenlos starten →